Vangaurd 360 Revision TKA

Principal Investigator: Jeremy Gililland
Keywords: Revision , Outcomes , Biomet Vangaurd , Total Knee Arthroplasty , TKA Department: Orthopedic Surgery
IRB Number: 00062862 Co Investigator: Christopher Peters
Specialty: Orthopaedic Surgery
Sub Specialties:
Recruitment Status: Enrolling by invitation

Contact Information

Michael Anderson
mike.anderson@hsc.utah.edu
801-213-3442

Brief Summary

The purpose of this study is to evaluate the performance of the Vanguard® SSK 360 revision knee utilizing offset on either the tibial component, femoral component, or both in terms of the restoration of mechanical alignment, clinical outcomes and survivorship.

 

Inclusion Criteria

Inclusion Criteria are identical to the indications for use stated in the FDA cleared labeling for the device in 510(k) K093293. These indications are stated below:

A.  Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis, where one or more compartments are involved;

B. Correction of varus, valgus or posttraumatic deformity;

C. Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of a previous total joint replacement procedure.

Patient selection factors to be considered include:

A. Need to obtain pain relief and improve function,

B. Ability and willingness of the patient to follow instructions, including control of weight and          activity level,

C. A good nutritional state of the patient, and

D. The patient must have reached full skeletal maturity.

Exclusion Criteria

Exclusion Criteria are identical to the contraindications for use stated in the FDA cleared labeling for the device in 510(k) K093293. These contraindications are stated below:

Absolute contraindications include: infection, sepsis, and osteomyelitis.

Relative contraindications include:

A. An uncooperative patient or a patient with neurologic disorders who is incapable of          following directions

B. Osteoporosis

C. Metabolic disorders which may impair bone formation

D. Osteomalacia

E. Distant foci of infections which may spread to the implant site

F. Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram    

G. Vascular insufficiency, muscular atrophy, neuromuscular disease

H. Incomplete or deficient soft tissue surrounding the knee.

Additional research-related exclusion criteria: patients who have a history of or current infection in the affected knee.